期刊文献+

慢性阻塞性肺疾病与支气管哮喘患者的气道可逆性分析 被引量:9

Analysis of airway reversibility between the chronic obstructive pulmonary disease and bronchial asthma patients
原文传递
导出
摘要 肺功能检测是判断气流受限重复性较好的客观指标,也是慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)诊断的核心标准,在COPD的诊断、严重程度评价、疾病进展、预后及治疗反应等方面具有重要意义。支气管舒张试验,反映了气道的“可逆性”,曾经是作为诊断支气管哮喘的重要指标,通常用于支气管哮喘和COPD的鉴别。但随着临床上对该检查方法的深入研究,
出处 《中华肺部疾病杂志(电子版)》 CAS 2014年第1期64-65,共2页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 国家自然科学基金(81071912) 十二五"863"重大专项分题(2012AA02A201) 重庆市自然科学基金(CSTC 2011BB5021) 第三军医大学临床医学科研项目(2012XLC08) 全军医学科技青年培育项目(13QNP117)
  • 相关文献

参考文献7

二级参考文献33

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8237
  • 2Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J,2008,31 :742- 750.
  • 3Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med,2007,101 : 1355-1362.
  • 4O' Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with " irreversible" emphysema. Eur Respir J, 2001,18:914-920.
  • 5GOLD committee. Global Strategy for the Diagnosis, Management and Prevention of COPD (update 2007 ). Global Initiative for Chronic Obstructive Lung Disease( www. goldcopd. com) ,2007,3.
  • 6Puente-Maestu L, Garcia de Pedro J, Martinez-Abad Y, et al. Dyspnea,ventilatory pattern, and changes in dynamic hyperinflation related to the intensity of constant work rate exercise in COPD. Chest ,2005,128:651-656.
  • 7Girard WM, Light RW. Should the FVC be considered in evaluating response to bronchodilator. Chest, 1983,84:87-89.
  • 8Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J, 1998,12 : 799-804.
  • 9Soriano JB, Mannino DM. Reversing concepts on COPD irreversibility. Eur Respir J,2008,31 : 695-696.
  • 10Eden E, Hammel J, Rouhani FN, et al. Asthma features in severe alphal-antitrypsin deficiency: experience of the National Heart, Lung,and Blood Institute Registry [ J]. Chest, 2003,123 : 765 - 771.

共引文献27

同被引文献87

  • 1沈锋,赵鸣武,贺蓓,杨京京,裴斐,王玉柱.白细胞介素17在大鼠慢性阻塞性肺疾病和支气管哮喘模型中的变化及意义[J].中华结核和呼吸杂志,2004,27(10):654-658. 被引量:38
  • 2胡苏荣,杨俊玲.肺弥散功能测定鉴别支气管哮喘和慢性阻塞性肺气肿[J].疑难病杂志,2004,3(6):363-364. 被引量:4
  • 3丁艳苓,姚婉贞.白三烯B4与肺部疾病[J].临床内科杂志,2005,22(11):790-792. 被引量:7
  • 4ZHOU Xin,DING Feng-ming,LIN Jiang-tao,YIN Kai-sheng,CHEN Ping,HE Quan-ying,SHEN Hua-hao,WAN Huan-ying,LIU Chun-tao,LI Jing,WANG Chang-zheng.Validity of Asthma Control Test in Chinese patients[J].Chinese Medical Journal,2007(12):1037-1041. 被引量:48
  • 5Fletcher C, Peto R. The natural history of chronic airflow obstruction[ J]. Br Med J, 1977,1 (6077) : 1645-1648.
  • 6Casanova C, de Torres JP, Aguirre-Jafme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort [J]. Am J Respir Crit Care Med, 2011,184(9) :1015-1021.
  • 7Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test[ J]. Eur Respir J, 2009, 34(3 ) :648-654.
  • 8Zugck C, Krtiger C, Dtirr S, et al. Is the 6- minute walk test a reliable substitute for peak oxygen uptake in patients with dilatedeardiomyopathy? [J].Eur Heart J, 2000,21 (7) :540-549.
  • 9Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease [ J ]. N Engl J Med, 2008, 359 ( 15 ) : 1543-1554.
  • 10Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeteroL/flutieasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study[J]. Respir Res, 2009,10:59.

引证文献9

二级引证文献170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部